WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/102312    International Application No.:    PCT/AU2005/000587
Publication Date: 03.11.2005 International Filing Date: 27.04.2005
A61K 31/282 (2006.01), A61P 35/00 (2006.01)
Applicants: MAYNE PHARMA LIMITED [AU/AU]; Level 21, 390 St Kilda Road, Melbourne, VIC 3004 (AU) (For All Designated States Except US).
WHITTAKER, Darryl, Vanstone [ZA/AU]; (AU) (For US Only).
LIU, Aikun, Julie [AU/AU]; (AU) (For US Only).
CIAMPINI, Marisa [AR/AU]; (AU) (For US Only).
SPENCER, Allan, Harvey [GB/AU]; (AU) (For US Only)
Inventors: WHITTAKER, Darryl, Vanstone; (AU).
LIU, Aikun, Julie; (AU).
CIAMPINI, Marisa; (AU).
SPENCER, Allan, Harvey; (AU)
Agent: BLAKE DAWSON WALDRON PATENT SERVICES; Leavel 39, 101 Collins Street, Melbourne, VIC 3000 (AU)
Priority Data:
2004902190 27.04.2004 AU
2004904892 27.08.2004 AU
Abstract: front page image
(EN)There is provided a pharmaceutical liquid formulation for parental administration comprising: (a) greater than 5 mg/mL oxaliplatin; (b) water; and (c) at least an effective solubilising amount of a cyclodextrin. The invention further provides use of a pharmaceutical formulation in the treatment of cancer and a method for treating cancer in a patient which comprises administrating a therapeutic amount of a pharmaceutical formulation. A method for preparing a pharmaceutical liquid formulation of oxaliplatin is also disclosed.
(FR)L'invention concerne une composition pharmaceutique liquide, destinée à l'administration parentale, qui comprend (a) plus de 5 mg/mL d'oxaliplatine; (b) de l'eau; et (c) au moins une quantité de solubilisation de cyclodextrine. L'invention concerne également l'utilisation d'une formulation pharmaceutique dans le traitement du cancer et un procédé pour traiter le cancer chez un patient qui consiste à administrer une quantité thérapeutique d'une formulation pharmaceutique. L'invention concerne également un procédé de préparation d'une formulation pharmaceutique liquide à base d'oxaliplatine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)